All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT

Area of Science:

• Cardiovascular Medicine
• Clinical Trials
• Epidemiology

Background:

• The association between cholesterol levels and stroke risk is less established than for myocardial infarction.
• Interpreting results from cholesterol-lowering trials has been challenging due to this uncertainty.
• Previous meta-analyses provided predictions for stroke risk reduction based on lipid-lowering interventions.

Purpose of the Study:

• To incorporate data from the IMPROVE-IT trial into existing meta-analyses on cholesterol and stroke.
• To validate previous predictions of stroke risk reduction with updated data.
• To provide a robust dataset for predicting stroke outcomes in ongoing and future trials.

Main Methods:

• Meta-analysis of original trial data combined with new data from the IMPROVE-IT trial.
• Comparison of observed stroke risk reduction with predicted risk reduction from meta-regression.
• Inclusion of data on total cholesterol reduction and hazard ratios for total stroke.

Main Results:

• The IMPROVE-IT trial data showed a 13.3% reduction in total cholesterol at one year.
• This reduction was associated with a hazard ratio of 0.86 for total stroke.
• The observed results closely align with the previously predicted relative risk of 0.90.

Conclusions:

• Updated meta-analysis incorporating IMPROVE-IT data confirms the strong relationship between cholesterol reduction and decreased stroke risk.
• The findings support the predictive accuracy of previous meta-regression models.
• These consolidated data are crucial for anticipating outcomes in trials evaluating new therapies like PCSK9 inhibitors.